Systemic and intratumoral 9-valent human papillomavirus vaccine treatment for squamous cell carcinoma in situ in a renal transplant recipient

Abstract

The incidence of cutaneous squamous cell carcinoma in situ (SCCIS) is high and increasing. Surgery, considered the gold standard, may not always be an option because of the size or location, associated comorbidities, or cost. Solid organ transplant recipients (SOTRs) have an increased risk of skin cancer, especially SCCs, often have multiple lesions simultaneously, and have significant medical comorbidities. We present an 87-year-old SOTR with a large SCCIS on the left hand successfully treated with combined systemic and intratumoral administration of the 9-valent human papillomavirus (HPV) vaccine (Gardasil 9, Merck & Co Inc, Miami Lakes, FL).